Posted by Michael Wonder on 02 Nov 2023
Health Canada approves Ultomiris for adults with neuromyelitis optica spectrum disorder
1 November 2023 - Ultomiris transforms the treatment landscape for anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder patients, with potential to eliminate relapses and improve outcomes.
Ultomiris (ravulizumab) has been approved by Health Canada as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
